journal article·2023-05-10Open access

Neural Stem Cells as Carriers of Nucleoside-Conjugated Nanogels: A New Approach toward Cell-Mediated Delivery

Agnieszka Morgenroth, Fatima Baazaoui, Aisa Hosseinnejad, Laura Schäfer, Andreas Vogg, Smriti Singh, Felix M. Mottaghy

ACS Applied Materials & Interfaces· Volume 15· Issue 18

Abstract

Neural stem cells (NSCs) present attractive natural drug delivery systems (DDSs). Their migratory potential enables crossing of the blood-brain barrier and efficient and selective accumulation near malignant cells. Here, we present the potential of NSCs as DDSs for nucleoside analogue-conjugated nanogels (NGs). Two different approaches were investigated: the intracellular loading and extracellular cell surface decoration with NGs. For both designs, the tumor-specific migratory potentials of NSCs remained unchanged; however, the intracellular loading showed a shorter NG retention. The cell surface decoration protocol yielded a high loading capacity of 100% after 1 h and a prolonged drug retention. A redox-sensitive linker between NGs and the nucleoside analogue 5-ethynyl-2'-deoxycytidine (EdC) allowed a tumor environment-specific drug release and its efficient and preferential incorporation into the DNA of the tumor cells. Interestingly, the tumor-trafficking potentials of NSCs were significantly potentiated by irradiation of tumor cells. In conclusion, this study indicates the potentials of cell surface-decorated NSCs as DDSs for tumor-specific release, cellular uptake, and incorporation of EdC into DNA.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Neurogenesis and neuroplasticity mechanisms · RNA Interference and Gene Delivery · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Nuclear Medicine, RWTH Aachen University, 52074 Aachen, Germany

DWI − Leibniz-Institute for Interactive Materials, RWTH Aachen University, 52074 Aachen, Germany

Max Planck Institute for Medical Research, Heidelberg 69120, Germany

Department of Nuclear Medicine, Maastricht University Medical Centre, 6229 HX Maastricht, Netherlands

Funding

Deutsche Forschungsgemeinschaft

References (45)

Show source-provided references
1. 10.1073/pnas.97.23.1284610.1073/pnas.97.23.12846 ↗
2. 10.1038/7471010.1038/74710 ↗
3. 10.1371/journal.pone.000002310.1371/journal.pone.0000023 ↗
4. 10.1002/sctm.16-039710.1002/sctm.16-0397 ↗
5. 10.1038/mt.2008.29010.1038/mt.2008.290 ↗
6. 10.1186/2052-8426-2-3110.1186/2052-8426-2-31 ↗
7. 10.3390/ijms2205225810.3390/ijms22052258 ↗
8. 10.1002/smll.20130111110.1002/smll.201301111 ↗
9. 10.1021/nn505147w10.1021/nn505147w ↗
10. 10.1016/S1470-2045(02)00788-X10.1016/S1470-2045(02)00788-X ↗
11. Chen W. · J. Nucl. Med. · 2005 · 46 · 946
12. 10.1016/S0360-3016(97)00770-010.1016/S0360-3016(97)00770-0 ↗
13. Dupertuis Y. M. · Cancer Res. · 2001 · 61 · 7971
14. Kassis A. I. · Q J. Nucl. Med. · 1996 · 40 · 301
15. 10.1158/1078-0432.CCR-08-090710.1158/1078-0432.CCR-08-0907 ↗
16. 10.18632/oncotarget.212310.18632/oncotarget.2123 ↗
17. 10.1002/smll.20170409310.1002/smll.201704093 ↗
18. 10.1038/nn117210.1038/nn1172 ↗
19. 10.1016/j.ajpath.2017.08.03110.1016/j.ajpath.2017.08.031 ↗
20. 10.1038/nnano.2013.2310.1038/nnano.2013.23 ↗
21. 10.1016/j.biomaterials.2009.09.06010.1016/j.biomaterials.2009.09.060 ↗
22. 10.1016/j.biomaterials.2015.03.00110.1016/j.biomaterials.2015.03.001 ↗
23. 10.1523/JNEUROSCI.08-04-01144.198810.1523/JNEUROSCI.08-04-01144.1988 ↗
24. 10.1371/journal.pone.023461410.1371/journal.pone.0234614 ↗
25. 10.1038/nm.219810.1038/nm.2198 ↗
26. 10.1021/acsabm.0c0161910.1021/acsabm.0c01619 ↗
27. 10.3389/fragi.2021.69068610.3389/fragi.2021.690686 ↗
28. 10.2174/138161282166615030211390610.2174/1381612821666150302113906 ↗
29. 10.1155/2021/850202110.1155/2021/8502021 ↗
30. 10.2967/jnumed.115.16300610.2967/jnumed.115.163006 ↗
31. 10.5966/sctm.2013-004910.5966/sctm.2013-0049 ↗
32. 10.2217/fon.13.21710.2217/fon.13.217 ↗
33. Roelcke U. · J. Nucl. Med. · 2002 · 43 · 1444
34. 10.1002/adhm.20210081210.1002/adhm.202100812 ↗
35. 10.1124/mol.59.5.118110.1124/mol.59.5.1181 ↗
36. 10.1158/1078-0432.CCR-09-315110.1158/1078-0432.CCR-09-3151 ↗
37. 10.1039/C7RA10151A10.1039/C7RA10151A ↗
38. 10.3390/cancers1105068810.3390/cancers11050688 ↗
39. 10.1016/j.ymeth.2011.06.00910.1016/j.ymeth.2011.06.009 ↗
40. 10.1002/stem.54310.1002/stem.543 ↗
41. 10.1002/glia.2032610.1002/glia.20326 ↗
42. 10.1002/1439-2054(20020401)287:4<223::AID-MAME223>3.0.CO;2-Z10.1002/1439-2054(20020401)287:4<223::AID-MAME223>3.0.CO;2-Z ↗
43. 10.1016/j.msec.2017.02.08810.1016/j.msec.2017.02.088 ↗
44. 10.1002/advs.20180061410.1002/advs.201800614 ↗
45. 10.1016/j.ab.2011.05.03710.1016/j.ab.2011.05.037 ↗